Natural products have been touted as important tools because of their vast potential for the development of compounds with antimicrobial activity and the possible inhibitory activity and/or adjuvant resistance mechanisms. Propolis has been empirically used for many years for the treatment of diseases, mainly due to its antioxidant, anti inflammatory and antimicrobial activities. This study aimed to evaluate the in vitro antimycobacterial activity of the ethanol extract of propolis alone and in combination with rifampicin (RIF), amikacin (AMI) and ciprofloxacin (CIP). The ethanol extract of propolis showed antibacterial activity against Mycobacterium chelonae and M. kansasii and was capable of increasing AMI, RIF and CIP activity in combination. On the other hand, compared to M. absecessus, M. fortuitum and M. avium, the extract was not active at 200 µg/mL and did not show pronounced adjuvant capacity when evaluated in association with the drugs. Based on these results, it can be concluded that the ethanol extract of propolis could be an alternative in the development of new drugs and can be used complementary with the current mycobacteriosis treatment.
Introduction: Bronchiectasis is a chronic respiratory disease that is largely related to inflammatory processes, irreversible dilation of the bronchi and the presence of recurrent lung infections. Furthermore, the disease presents a wide geographic, prevalence and etiological variability, driving the need for local assessments that aim to understand the disease and its behavior in different regions of the world. Objective: To carry out a first approach to the prevalence profile of the disease in the extreme south of Brazil. Method: Census study evaluating the clinical, sociodemographic profile and prevalence of bronchiectasis in patients treated at a regional reference pulmonology outpatient clinic. Result: Of the 95 patients eligible for the study, 21 were classified as bronchiectatic through tomographic diagnosis. The majority of patients were women (67%), caucasian (86%), and aged between 61 and 80 years (62%). Regarding the diseases and symptoms reported by patients, a considerable presence of post-tuberculosis patients (40%) could be identified. Furthermore, the performance of pneumococcal vaccination was also a variable that showed a significant difference, where 55% of diagnosed patients did not undergo vaccination. Conclusion: This study allows the development of a population-based study, guiding health policies that favor the monitoring and quality of life of these patients